Drugs / CIT-013
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07499908 | May → Aug 2026 overdue | — | Citryll BV | Not yet recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07147959 | Jan → Oct 2026 expected | rheumatoid arthritis | Citryll BV | Recruiting | No outcome recorded |
| Phase 2 | NCT06993233 | Oct 2025 → Apr 2027 expected | hidradenitis suppurativa | Citryll BV | Recruiting | No outcome recorded |
| Phase 2 | NCT06567470 | Jul 2025 → Apr 2027 expected | rheumatoid arthritis | Citryll BV | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-27 | Citryll BV | Results Citryll presents positive data from phase I study of CIT-013 in Rheumatoid Arthritis at ACR convergence 2025 citryll.com ↗
The featured poster highlights findings from Citryll’s Phase I clinical trial of CIT-013 in participants with RA and healthy volunteers, which demonstrated that CIT-013 was generally well tolerated across all participants, with no serious treatment-related events reported. |
| 2025-02-20 | Citryll BV | Results Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders citryll.com ↗
The study demonstrates that CIT-013, originally developed to target NETs, also effectively inhibits the formation of eosinophil extracellular traps (EETs) with the same potency and verifies the presence of CIT-013’s epitope on EETs. |
| 2020-03-20 | Citryll BV | Results Landmark paper on Citryll’s NET inhibitor programme published in Nature’s Cellular and Molecular Immunology citryll.com ↗
The publication describes 5 non-clinical in vivo pharmacological studies, as well as human Rheumatoid Arthritis (RA), Systemic lupus erythematosus (SLE) and mouse in vitro NET formation pharmacology. |
All press releases naming this drug 11 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIT-013 | “CIT-013 is a novel humanized monoclonal antibody designed to inhibit NET release and enhance phagocytosis, offering a new potential therapeutic strategy for RA and HS.” NCT07147959 ↗ |
| Modality | Monoclonal antibody | “CIT-013 is an IgG1k monoclonal antibody consisting of two identical light chain polypeptides composed of 219 amino acids each and two identical heavy chain polypeptides...” NCT07499908 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT06567470 ↗ |